Pfizer Inc (PFE.N), which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines. The largest U.S. drugmaker said its lengthy analysis determined that splitting off its low-growth generics from its patent-protected branded products would not boost cash flow or better position the businesses competitively. The move would also disrupt operations, have inherent costs and fail to deliver any tax efficiencies, the company said.

 

 

 

Photo: www.sandiegouniontribune.com

Нашли ошибку в тексте? Выделите её мышкой и нажмите: Ctrl + Enter



Related

Comments